Who is sponsoring NCT05727410?

NCT05727410 is sponsored by Myung-Ju Ahn.

What drugs are being tested in NCT05727410?

Interventions in NCT05727410: nivolumab, docetaxel, cisplatin Group.

What condition does NCT05727410 study?

NCT05727410 studies High-grade Salivary Gland Carcinoma.

Is NCT05727410 still recruiting?

NCT05727410 is currently recruiting now. Last updated 14 February 2023.

Last reviewed 2023-02-14 · How we verify

NCT05727410

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

Recruiting now Phase 2 Last updated 14 February 2023

What this trial tests

Phase 2 trial testing nivolumab, docetaxel, cisplatin Group in High-grade Salivary Gland Carcinoma in 50 participants. Currently enrolling.

Timeline

15 November 2022

Primary endpoint
31 August 2026

31 August 2026

Quick facts

Lead sponsor	Myung-Ju Ahn
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	15 November 2022
Primary completion	31 August 2026
Estimated completion	31 August 2026
Sites	1 location across South Korea

Drugs / interventions tested

nivolumab, docetaxel, cisplatin Group — full drug profile →

Conditions studied

High-grade Salivary Gland Carcinoma — all drugs for High-grade Salivary Gland Carcinoma →

Sponsor

Myung-Ju Ahn — full company profile →

Who can join

19 and older, any sex, with High-grade Salivary Gland Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Primary Objective: \- Major pathologic response rate defined by ≤ 10% of tumor composed of viable tumor 2. Secondary Objectives: * Complete resection rate * Response rate to neoadjuvant therapy according to RECIST 1.1 * Downstaging at pathologic staging compared to clinical staging performed at study entry * Distant metastasis free survival (DMFS) rate at 2 years * Disease free survival at 2 years * Overall survival rate at 2 years * Safety and feasibility 3. Exploratory Objectives: * PD L1 expression by 28-8 immunohistochemistry * IHC (HER2, AR, etc) * Whole exome sequencing (WES) * Whole transcriptome sequencing (WTS) * Peripheral blood biomarkers (CD4+ T cells, CD8+ T cell, myeloid derived suppressor cells (MDSC), Treg etc) * Interferon gamma related gene expression profile * Multiplex florescence measure of tumor cells and tumor microenvironment cells

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05727410 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Myung-Ju Ahn
Last refreshed: 14 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05727410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing